
ASX Release

Anatara completes \$0.66m Placement and announces a Share Purchase Plan to raise a further \$0.5m

Key Highlights:

- Anatara has received firm commitments to raise \$660,000 through the proposed issue of 13,200,000 ordinary shares at \$0.05 per share (**Placement**) reflecting strong support from existing institutional and sophisticated investors.
- In addition, Anatara Lifesciences announces a Share Purchase Plan (**SPP**) to raise a target amount of \$500,000 through the issue of 10,000,000 ordinary shares at \$0.05 per share.
- Funds raised from the Placement and the SPP will be used to finish the pivotal Phase II clinical study of Anatara's GaRP (*Gastrointestinal ReProgramming*) complementary medication in irritable bowel syndrome (IBS) and to progress an anti-obesity proof of concept project.
- Given the unmet need for an effective treatment for IBS, Anatara anticipates strong commercial interest the Company's patent protected GaRP product provided Stage 2 corroborates the Stage 1 results.
- Stage 2 of the GaRP-IBS trial is the planned extension that follows the successful completion of 61 patients in Stage 1 of the Phase II trial which reported greater than a 50% reduction in IBS symptoms and with safety profile confirmed.

ADELAIDE, 15 November 2024: Anatara Lifesciences (ASX: ANR) ("**Anatara**" or "**the Company**"), a developer of evidence-based solutions for gastrointestinal diseases in humans, is pleased to announce Anatara has received firm commitments to raise \$660,000 (before costs) through the proposed issue of 13,200,000 ordinary shares at \$0.05 per share (**Placement**) to new and existing sophisticated and institutional investors. In addition, Anatara Lifesciences announces it is launching a Share Purchase Plan (**SPP**) at the same price as the Placement, targeting proceeds of \$500,000 (before costs) through the issue of up to 10,000,000 ordinary fully paid shares at \$0.05 per share (with the ability to accept oversubscriptions at directors' discretion but capped at \$30,000 of ordinary fully paid shares per eligible holder).

Placement

Anatara has received firm commitments to raise \$660,000 through the proposed issue of 13,200,000 new fully paid ordinary shares ("**Placement Shares**") at \$0.05 per share to new and existing sophisticated and institutional investors. It is proposed that the issue of 13,200,000



Placement Shares will occur on Friday 22 November 2024, subject to the receipt of funds on or before Thursday 21 November 2024.

The issue price of \$0.05 per Placement Share represents a discount of 18.0% to the past 5 day VWAP price of Anatara shares on which trades were recorded and a discount of over 10% to the 30 day VWAP of \$0.0559. The allotment of the Placement Shares will be issued within Anatara's 15% placement capacity under ASX Listing Rule 7.1. The Placement Shares will rank equally with existing fully paid shares in Anatara. No Placement Shares will be issued in the Placement to a related party or otherwise to any person referred to in Listing Rule 10.11.

Taylor Collison Limited was the Lead Manager and Bookrunner to the Placement. Candour Advisory acted as Advisor to the Company. The Placement was not underwritten.

Taylor Collison Limited will receive an overall total gross fee of 6% on the Placement amount and 3% of the SPP Offer Proceeds with an additional 3% for funds allocated to Taylor Collison Limited clients in the SPP.

Taylor Collison Limited will also receive 1,000,000 options (**Options**). The Options will have an exercise price of 0.075c, can be exercised immediately and will expire 3 years following their issue. The Options are being issued for financial services as part of the Placement and the SPP process. These Options will be allocated under the Company's existing Listing Rule 7.1 capacity.

Share Purchase Plan

Anatara will give eligible shareholders an opportunity to subscribe for new fully paid ordinary shares (**SPP Shares**) in Anatara by way of an SPP. The issue price of the SPP Shares will be same as the Placement i.e. \$0.05 per share.

Under the SPP, each shareholder who held shares in Anatara at 7:00 p.m. (Melbourne time), on Thursday 14 November 2024 and who has a registered address in Australia or New Zealand will be entitled to acquire up to \$30,000 of SPP Shares without brokerage. The SPP will raise a target amount of \$500,000 (before costs) with the ability to accept over subscriptions, noting the cap of \$30,000 of SPP Shares for each shareholder.

Anatara Directors that hold Shares, may participate in the SPP.

Full details of the SPP (including details of any scale back in the event of oversubscription) will be set out in the SPP Offer Booklet which is expected to be released to ASX and despatched to eligible shareholders on Wednesday 27 November 2024.

Use of Funds

Funds raised from the Placement and the SPP will be used to finish the pivotal Phase II clinical study of Anatara's GaRP (*Gastrointestinal ReProgramming*) complementary medication for irritable bowel syndrome (IBS) and to further readiness for manufacturing. There will also be



approximately \$250,000 allocated to an anti-obesity proof of concept project. The anti-obesity project has been designed to develop an oral medication to assist weight reduction and sustaining weight control in conjunction with other contemporary treatments and approaches.

Key Dates

The key dates for the Placement and SPP are as follows:

Record Date (for the SPP)	7:00 p.m. (Melbourne time), on Thursday 14 November 2024
Announcement of Placement and SPP and recommencement of trading of Shares on the ASX	Friday 15 November 2024
Settlement of Placement Shares	Thursday 21 November 2024
Issue of Placement Shares	Friday 22 November 2024
Despatch of SPP Offer Booklet	Wednesday 27 November 2024
SPP Opens	Wednesday 27 November 2024
SPP closes	Wednesday 18 December 2024
Results of SPP announced to the ASX	Tuesday 23 December 2024
Issue of Shares under the SPP	Tuesday 23 December 2024

About GaRP

Anatara's GaRP product is a multi-component, multi-coated complementary medicine designed to address underlying factors associated with chronic gastrointestinal conditions such as IBS and IBD. GaRP is the working name for the product from the Company's **Gastrointestinal ReProgramming** project that was designed to assist restoration and maintenance of the gastrointestinal tract (GIT) lining as a barrier and assist the homeostasis of the microbiome. The product is made of GRAS (Generally Regarded As Safe) components.

For more information please contact:

Dr. David Brookes
Chair, Anatara Lifesciences Ltd
+61 (0) 411 712 579
dbrookes@anatara.com

Dirk van Dissel
Candour Advisory – Investor Relations
+61 (0) 408 326 367
dirk@candouradvisory.com.au



About Anatara Lifesciences Ltd

Anatara Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based health products where there is significant unmet need. Anatara is focused on building a pipeline of human health products with a particular focus on conditions that involve the complexity of the gastrointestinal tract. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

Disclaimer

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anatara Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation, and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.

Anatara Lifesciences Limited

Registered Office

C/-PERKS Level 8,81 Flinders Street, Adelaide SA 5000

Email info@anatara.com | Website anataralifesciences.com

